Form 8-K - Current report:
SEC Accession No. 0001193125-24-194957
Filing Date
2024-08-06
Accepted
2024-08-06 16:54:30
Documents
17
Period of Report
2024-08-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d876057d8k.htm   iXBRL 8-K 27676
2 EX-5.1 d876057dex51.htm EX-5.1 10108
6 GRAPHIC g876057dsp4bb.jpg GRAPHIC 22954
7 GRAPHIC g876057g0806080609921.jpg GRAPHIC 1631
8 GRAPHIC g876057g0806080610102.jpg GRAPHIC 1867
  Complete submission text file 0001193125-24-194957.txt   205049

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inzy-20240806.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20240806_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20240806_pre.xml EX-101.PRE 11707
19 EXTRACTED XBRL INSTANCE DOCUMENT d876057d8k_htm.xml XML 3762
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 241180211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)